|Bid||38.06 x 1200|
|Ask||38.23 x 1800|
|Day's Range||37.90 - 38.27|
|52 Week Range||33.26 - 42.68|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||13.08|
|Earnings Date||Feb. 01, 2017 - Feb. 06, 2017|
|Forward Dividend & Yield||2.17 (5.41%)|
|Ex-Dividend Date||May 20, 2021|
|1y Target Est||48.04|
LONDON, September 28, 2021--FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
Sanofi is dropping plans for its own mRNA-based COVID-19 vaccine because of the dominance achieved by BioNTech-Pfizer and Moderna in using the technology to fight the pandemic, the company said on Tuesday. The move highlights the challenges of competing in particular with pioneer BioNTech, which rose from obscurity through its alliance with pharma major Pfizer last year. French healthcare group Sanofi will instead focus on efforts with British partner GlaxoSmithKline to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach, where mass trials are ongoing.
Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.